A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis. - NA

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2008
This article has no abstract
Epistemonikos ID: 365cac88f82e4603bae2f36a28a5eb6ee255714b
First added on: Apr 16, 2025